
Accuray Incorporated ARAY
$ 0.89
-0.47%
Quarterly report 2025-Q3
added 11-05-2025
Accuray Incorporated Gross Profit 2011-2026 | ARAY
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Accuray Incorporated
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 147 M | 143 M | 154 M | 160 M | 160 M | 150 M | 163 M | 162 M | 141 M | 159 M | 145 M | 143 M | 97.6 M | 137 M | 107 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 163 M | 97.6 M | 145 M |
Quarterly Gross Profit Accuray Incorporated
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26.5 M | - | 31.6 M | 41.9 M | 34.5 M | - | 29.1 M | 35.9 M | 39.5 M | - | 38.7 M | 43 M | 34.6 M | 77.6 M | 34.8 M | 42.6 M | 39.5 M | 82.2 M | 39.5 M | 40.8 M | 35.4 M | 40.8 M | 35.4 M | 37.9 M | 32.9 M | 37.9 M | 32.9 M | 38.4 M | 37.9 M | 38.4 M | 37.9 M | 39.4 M | 38.1 M | 39.4 M | 38.1 M | 31.4 M | 31.3 M | 31.4 M | 31.3 M | 42.6 M | 33.9 M | 42.6 M | 33.9 M | 38.5 M | 27.8 M | 38.5 M | 27.8 M | 38.2 M | 26.5 M | 38.2 M | 26.5 M | 26.6 M | 23.7 M | 26.6 M | 23.7 M | 40.2 M | 24.4 M | 40.2 M | 24.4 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 82.2 M | 23.7 M | 36.5 M |
Gross Profit of other stocks in the Medical devices industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Abiomed
ABMD
|
690 M | - | - | $ 17.2 B | ||
|
Acutus Medical
AFIB
|
-3.14 M | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
443 K | - | 3.58 % | $ 2.21 M | ||
|
Apollo Endosurgery
APEN
|
42.4 M | - | - | $ 475 M | ||
|
Cognyte Software Ltd.
CGNT
|
247 M | $ 9.57 | 0.1 % | $ 687 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
67.9 M | - | - | $ 1.77 B | ||
|
Alphatec Holdings
ATEC
|
424 M | $ 22.65 | -0.15 % | $ 3.24 B | ||
|
AxoGen
AXGN
|
142 M | $ 33.63 | 0.78 % | $ 1.49 B | ||
|
Axonics Modulation Technologies
AXNX
|
198 M | - | - | $ 3.31 B | ||
|
Apyx Medical Corporation
APYX
|
33.8 M | $ 3.5 | 1.16 % | $ 121 M | ||
|
EDAP TMS S.A.
EDAP
|
26.6 M | $ 3.66 | -3.56 % | $ 136 M | ||
|
Electromed
ELMD
|
50 M | $ 28.9 | -0.41 % | $ 244 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
584 K | - | -5.86 % | $ 30.6 M | ||
|
Bio-Rad Laboratories
BIO
|
342 M | $ 323.76 | 1.47 % | $ 9.13 B | ||
|
BioSig Technologies
BSGM
|
229 K | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
11.5 B | $ 97.6 | -0.79 % | $ 144 B | ||
|
CONMED Corporation
CNMD
|
733 M | $ 43.07 | -2.56 % | $ 1.33 B | ||
|
Conformis
CFMS
|
23.2 M | - | - | $ 16.4 M | ||
|
Bruker Corporation
BRKR
|
1.65 B | $ 54.12 | 3.12 % | $ 8.06 K | ||
|
Abbott Laboratories
ABT
|
18.7 B | $ 125.84 | -0.27 % | $ 219 B | ||
|
InMode Ltd.
INMD
|
317 M | $ 14.47 | 1.47 % | $ 1.15 B | ||
|
CryoLife, Inc.
CRY
|
168 M | - | -4.14 % | $ 702 M | ||
|
IRIDEX Corporation
IRIX
|
21.8 M | $ 1.16 | -2.94 % | $ 18.7 M | ||
|
Cardiovascular Systems
CSII
|
173 M | - | 0.15 % | $ 844 M | ||
|
Cutera
CUTR
|
-12.7 M | - | -10.19 % | $ 1.99 M | ||
|
LENSAR
LNSR
|
14.1 M | $ 11.6 | -0.6 % | $ 134 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
28.7 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
43.7 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
1.99 M | - | - | $ 111 M | ||
|
Dynatronics Corporation
DYNT
|
6.01 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
14.3 M | - | - | $ 10.2 M | ||
|
Orthofix Medical
OFIX
|
546 M | $ 15.77 | -2.65 % | $ 601 M | ||
|
Intersect ENT, Inc.
XENT
|
50.2 M | - | - | $ 955 M | ||
|
Second Sight Medical Products
EYES
|
500 K | - | -0.97 % | $ 54.4 M | ||
|
GBS
GBS
|
1.25 M | - | -0.57 % | $ 7.12 M | ||
|
Align Technology
ALGN
|
2.8 B | $ 172.23 | 0.97 % | $ 12.9 B | ||
|
IRadimed Corporation
IRMD
|
56.3 M | $ 98.81 | -1.19 % | $ 1.25 B | ||
|
Avinger
AVGR
|
2 M | - | -20.74 % | $ 369 K | ||
|
ClearPoint Neuro
CLPT
|
19.1 M | $ 15.06 | -1.63 % | $ 407 M | ||
|
FONAR Corporation
FONR
|
42.4 M | $ 18.56 | 0.02 % | $ 122 M | ||
|
Sintx Technologies
SINT
|
1.84 M | $ 3.78 | -1.32 % | $ 14.1 M | ||
|
Sensus Healthcare
SRTS
|
24.4 M | $ 4.82 | 8.8 % | $ 78.6 M | ||
|
Globus Medical
GMED
|
719 M | $ 94.0 | -0.66 % | $ 12.8 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
953 M | $ 13.69 | -1.23 % | $ 1.05 B | ||
|
Stryker Corporation
SYK
|
4.17 B | $ 369.46 | 0.61 % | $ 141 B |